US › Healthcare

Fortress Biotech Inc (FBIO)

US · Healthcare · Biotechnology

$2.51+2.03%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$18.7M

Revenue YoY

+14.0%

Net profit

$-468,000

Profit YoY

-103.0%

EPS

$-0.08

EPS estimate

$-0.20

Net margin

-2.5%

EPS came in at -0.08 against a street estimate of -0.20 — a beat of 60.0%.

Key statistics

Market cap

$83.0M

P/E

0.9

Forward P/E

1.2

P/B

0.51

Book value

$4.93

EPS (TTM)

$2.74

52-week high

$4.53

52-week low

$2.18

50-day MA

$2.98

200-day MA

$3.01

Beta

1.19

Analyst view

Analysts rate Fortress Biotech Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $11.00.

Shareholding

Insiders

22.70%

Institutions

31.35%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	2.90%
Opaleye Management Inc	2.67%
GSA Capital Partners LLP	1.37%
Shikiar Asset Management Inc	0.92%
Geode Capital Management, LLC	0.87%
Northern Trust Corp	0.69%
Two Sigma Investments LLC	0.64%
Susquehanna International Group, LLP	0.63%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Fortress Biotech Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.